35 percent of patients with breast cancer worried about genetic risks to themselves, family members
the ONA take:
According to a new study conducted at the University of Michigan Comprehensive Cancer Center in Ann Arbor, Michigan, researchers have found that a third of women diagnosed with breast cancer are concerned about the genetic risk of a family member developing cancer or developing other cancers themselves.
For the study, researchers surveyed 1,536 women who had been treated for breast cancer that were included in the Surveillance, Epidemiology and End Results (SEER) databases.
Results showed that 35% of women with breast cancer expressed a strong desire for genetic testing, while 43% did not have a discussion about genetic testing with a health care professional.
The study also found that racial minority participants were less likely than white patients to discuss genetic testing with a health care professional despite a strong desire to do so.
Researchers found that many patients, particularly Latinas who spoke only Spanish, were concerned that their loved ones might get breast cancer in the future due to inherited risk.
Study results were published in the Journal of Clinical Oncology.
A third of women diagnosed with breast cancer are concerned about the genetic risk of a family member developing cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|